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Background: It has been postulated that LXR activation would increase the benefits of LDL-lowering interventions on cardiovascular risk. We 
studied the effect of LXR-623, an oral LXR agonist, on plaque progression/regression in a model of advanced atherosclerosis.
Methods: Abdominal aortic lesions (9months 0.2% cho-diet and balloon denudation) were induced in NZW rabbits (n=41). All animals underwent 
a MRI (baseline) to assess the severity of the induced lesions; then they were randomized to placebo, simvastatin (simva, 5mg/Kg/day), LXR (1.5 
and 5 mg/Kg/day) or LXR-623 (1.5 mg/kg) +simva combination. The effect of the treatments was expressed as % change in MRI-plaque burden 
after 6 months of treatment vs baseline. Plaque composition (macrophages and SMC) was studied by immunostaining.
Results: Simva significantly reduced plaque progression vs placebo. LXR-623 alone induced a similar effect on plaque progression without altering 
plasma lipids. Preliminary data showed a significant lesion regression by LXR-623+simva combination (Fig 1). Macrophages were significantly 
(p<0.05) reduced by simva (20%) as well as LXR 5 (18%) and combination (22%) vs placebo. SMC density was unchanged by all treatments.
Conclusions: LXR-623 inhibits lesion progression similar to simvastatin. Of interest, LXR-623+simva combination showed a synergism that 
regressed previously induced lesions Our data suggest that LXR-623 is a promising antiatherosclerotic agent, especially when combined with statins.
